Canada markets closed
  • S&P/TSX

    21,173.45
    -111.39 (-0.52%)
     
  • S&P 500

    4,574.79
    +8.31 (+0.18%)
     
  • DOW

    35,756.88
    +15.73 (+0.04%)
     
  • CAD/USD

    0.8071
    -0.0001 (-0.02%)
     
  • CRUDE OIL

    84.39
    -0.26 (-0.31%)
     
  • BTC-CAD

    75,093.80
    -3,586.34 (-4.56%)
     
  • CMC Crypto 200

    1,468.96
    -36.19 (-2.40%)
     
  • GOLD FUTURES

    1,795.30
    +1.90 (+0.11%)
     
  • RUSSELL 2000

    2,296.08
    -16.56 (-0.72%)
     
  • 10-Yr Bond

    1.6190
    -0.0160 (-0.98%)
     
  • NASDAQ futures

    15,554.75
    +9.75 (+0.06%)
     
  • VOLATILITY

    15.98
    +0.74 (+4.86%)
     
  • FTSE

    7,277.62
    +54.80 (+0.76%)
     
  • NIKKEI 225

    29,058.71
    -47.30 (-0.16%)
     
  • CAD/EUR

    0.6955
    -0.0002 (-0.03%)
     

ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ZY:
https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19787&from=5

Zymergen Inc. NEWS - ZY NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Zymergen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Zymergen you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Zymergen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ZY lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97401

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting